Anopheles Mosquitoes Exposed to Long-Acting Antimalarials via Drug-Supplemented Bloodmeal Absorb Drug but Do Not Suffer Fitness Costs
Open Access
- 15 June 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e952-e961
Abstract
Background: The World Health Organization's recommendations for antimalarial chemoprevention and mass treatment use in endemic areas have greatly expanded, allowing more flexibility in demographic groups and regions targeted. An overlooked aspect of expanding human population-level drug exposure is the downstream impact of a drug on the vector. Anopheles mosquitoes refeed often with ≥ 4 bloodmeals during their lifespan. This provides repeated opportunities for mosquitoes to ingest a drug via bloodmeals taken from people with antimalarials in the bloodstream and raises questions as to the drug’s impact on mosquitoes. Methods: We supplemented bloodmeals with physiologic levels of long-acting antimalarials to assess drug exposure impact on Anopheles mosquito fitness and determine drug absorption extent. Results: We did not observe any significant differences in mosquito feeding, behavior, fecundity, or viability after amodiaquine, desethylamodiaquine, piperaquine, and sulfadoxine-pyrimethamine ingestion in laboratory-reared Anopheles gambiae or field-derived Anopheles coluzzii mosquitoes. Interrogating drug distribution within mosquitoes utilizing liquid chromatography-tandem mass spectrometry, desethylamodiaquine, amodiaquine's longer-acting active metabolite, was fed at half and twice reported Cmax concentrations; the drug was dose-dependently detected in pooled whole mosquitoes, midguts, and hemolymph. This was statistically significant for whole mosquitoes harvested at 24 and 120 hours, and midguts harvested at 24 hours. Between 24 and 120 hours, the drug decreased in midguts but increased in hemolymph. Conclusions: We show sustained biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion without fitness costs. These studies provide a foundation to next assess vector-stage antimalarial drug exposure impact on parasite development in infected mosquitoes, which could in turn have implications for transmission dynamics and drug resistance spread.Keywords
Funding Information
- Ambrose Monell Foundation
- American Society of Tropical Medicine and Hygiene
- National Institutes of Health (K23AI193079)
- National Institutes of Health (5T32AI007517-24)
- National Center for Advancing Translational Sciences (UL1TR001863)
This publication has 46 references indexed in Scilit:
- The impact of blood on vector-borne diseases with emphasis on mosquitoes and sand fliesTrends in Parasitology, 2025
- The emergence of artemisinin partial resistance in Africa: how do we respond?The Lancet Infectious Diseases, 2024
- Targeting malaria parasites inside mosquitoes: ecoevolutionary consequencesTrends in Parasitology, 2022
- Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The GambiaThe Lancet Infectious Diseases, 2022
- Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational studyThe Lancet, 2020
- Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trialThe Lancet, 2019
- Pharmacokinetics‐Pharmacodynamics of High‐Dose Ivermectin with Dihydroartemisinin‐Piperaquine on Mosquitocidal Activity and QT‐Prolongation (IVERMAL)Clinical Pharmacology & Therapeutics, 2018
- Sulfadoxine-pyrimethamine pharmacokinetics in malaria: Pediatric dosing implicationsClinical Pharmacology & Therapeutics, 2006
- Ivermectin: An updateParasitology Today, 1985
- Amodiaquine as a prodrug: Importance of metabolite(s) in the antimalarial effect of amodiaquine in humansLife Sciences, 1985